Therapeutic Solutions International Universal Donor Immunotherapy StemVacs™ Activates Antiviral Immune Cells
June 30 2020 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International Universal Donor
Immunotherapy StemVacs™ Activates Antiviral Immune Cells While
Protecting Lungs From "Cytokine Storm"
Preclinical Experiments for Upcoming FDA Submission Reveal
Possible Dual Benefit in COVID-19 Model
OCEANSIDE, CA -- June
30, 2020 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today new data and a
patent filing showing its clinical-stage cancer immunotherapeutic
product StemVacs™ appears to reduce innate immune induced
inflammation in lungs while stimulating immune cells known to
possess antiviral properties.
StemVacs™ is a
cell-based
drug comprised of
dendritic cells activated in a proprietary manner which when
administered stimulates a type of immune system cell termed
"natural killer" or NK cells. Numerous studies have shown
that NK cells are involved in protecting the body from cancer and
from viruses. The FDA has allowed for clinical trials of COVID-19
patients using an NK cell-based drug termed CYNK-001
[1].
Immune therapy of COVID-19
patients has been considered by some as a double-edged sword.
On the one hand, it is desirable to augment immune responses to
control the virus, on the other hand, excessive immunity is known
to lead to acute respiratory distress syndrome (ARDS), which is a
major cause of death. The current animal data sought to replicate
the lungs of patients suffering from ARDS by treating mice with a
potent activator of the innate immune system molecule TLR4.
To the surprise of Company scientist's administration of StemVacs™
actually reduced the lung inflammation.
"Given the established safety
profile of StemVacs™ from our previous studies, as well as the
findings reported today, we are on track for advancing towards FDA
interactions," said Dr. James
Veltmeyer,
Chief Medical Officer of the Company.
"To my knowledge, the majority of immunotherapies have the
potential to cause lung inflammation through what is called
"cytokine storm". It may be that StemVacs™, operates through novel
molecular mechanisms due to our unique methods of preparing the
cells."
In contrast to traditional
dendritic cell-based immunotherapies, StemVacs™ can
be administered without the need for matching donor to recipient,
allowing for standardized manufacturing. Additionally,
StemVacs™ preparation involves "forcing" the dendritic cells to
mature by treatment with leukocyte derived extracts, which appears
to induce higher expression of immune-stimulatory molecules as
compared to standard approaches.
"We are pleased with the rapid
progress in the development of data and scientific rationale for
utilization of StemVacs™ for COVID-19 clinical trials,"
said
Timothy Dixon, President, and CEO of the Company. "Our philosophy
at TSOI is that the body knows best how to defend itself. Our
job is to just give it support to help
the immune system do what it naturally does. We are doing
this in our QuadraMune™ clinical trial and with StemVacs™ we hope
to do the same thing."
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com and for additional
info on QuadraMune™
visit www.areyoucovidmune.com/covidmune/.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
[1] https://www.prnewswire.com/news-releases/celularity-announces-fda-clearance-of-ind-application-for-cynk-001-in-coronavirus-first-in-cellular-therapy-301034141.html
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024